IL-21 in cancer immunotherapy: At the right place at the right time.
Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects.
['Santegoets|Saskia Jam|SJ|', 'Turksma|Annelies W|AW|', 'Powell|Daniel J|DJ|', 'Hooijberg|Erik|E|', 'de Gruijl|Tanja D|TD|']
IL-21 antigen presenting cell DC vaccination adoptive cell transfer common gamma-chain cytokine receptor family